Sanomune is a private biotech start-up focused on neurological and autoimmune diseases. The Company has two products entering Phase IIa clinical trials and a variety of product candidates in various stages of development. The Company’s core technology is based on the proprietary repurposing of a safe, orally delivered biological to treat multiple large market indications. Sanomune’s lead product, SAN-61, is a potential first-in-class treatment that triggers neural stem cell proliferation while targeting both amyloid plaque and neurofibrillary tangles, the dual hallmark pathologies of Alzheimer’s disease.

“Sanomune is honoured to be recognized as one of Canada’s Top 10 Life Science Companies,” stated Sanomune’s President, Rick Pauls. “Independent validation from a jury of experienced Canadian and US venture capitalists is highly valuable and we are proud to be included among such a respected, high-profile group of companies. As we continue to develop our pipeline and advance our Phase II clinical programs for Alzheimer’s disease and rheumatoid arthritis, we look forward to exploring the unique opportunities this award will create.”

Winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. Originally developed to promote the 10 most promising life science companies from across Canada to Canadian and international investors and partners, the competition now showcases Canada’s life sciences, cleantech and technology sectors. Working in partnership with Canadian Consulates in Boston, New York City, San Diego and San Francisco, winning companies will participate in targeted investment forums in each city, providing them with an opportunity to meet with Venture Capital investors who have expressed an active interest in financing these companies. Since its inception in 1999, competition alumni have secured more than $522M in venture capital financing.

Canada’s Top 10™ is organized by OCRI (Ottawa Centre for Research and Innovation) and presented by Borden Ladner Gervais LLP. The winners include a wide variety of companies from the life science, cleantech and technology sectors.

“OCRI is pleased to play an active role in the growth of so many exceptional Canadian companies,” said Michelle Scarborough, Vice President, Investment and Commercialization, OCRI. “This is a successful program as evidenced by the investment in past winners. Through our ongoing outreach to the rest of Canada, the best companies from three key innovation sectors can continue to benefit from exposure to VC’s, other investors and potential strategic partners.”

About Sanomune:
Sanomune is a private biotech start-up focused on neurological and autoimmune disorders. Sanomune’s lead product, SAN-61, is targeting the treatment of Alzheimer’s disease and other neurological conditions with a naturally-occurring, orally available protein.www.sanomune.com

About OCRI:
OCRI (Ottawa Centre for Research and Innovation), the city’s economic development corporation, is leading the way for Ottawa. OCRI is the rallying point to bring business, education and research together to create the winning economic conditions that allow Ottawa’s technology companies to thrive locally and compete globally. At OCRI, we promote sustainable economic development to maintain our high quality of life. For more information on OCRI visit our website at www.ocri.ca and for more information on the Ottawa Region please visit www.ottawaregion.com.

For information contact:

Rick Pauls
President
Sanomune Inc.
7-1250 Waverley St
Winnipeg, MB R3Y1W1
Tel: (204) 477-7590

Kim Cunningham
Manager, External Communications
OCRI
Tel: (613) 828-6274 x 256
Cell: (613) 851-0768

“We’re honoured to have been selected to present our results at the ICAD Hot Topics session,” said Rick Pauls, Sanomune’s President. “When combined with existing clinical data on SAN-61 and our recent data regarding MMP-9 activation, the evidence we have accumulated suggests SAN-61 could be an ideal Alzheimer’s therapy.” In addition to targeting soluble and fibril amyloid, in-vivo
research also appears to suggest that SAN-61 is involved in neuroregeneration and the regulation of tau protein through GSK-3beta inhibition. “This could be a therapy with multiple promising points of intervention.” Sanomune’s data can be viewed during ICAD’s Hot Topics Poster Session on Wednesday, July 30.

About ICAD – The Premier Alzheimer Conference
As a part of the Alzheimer’s Association research program, this international conference serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. This meeting will bring together more than 5,000 researchers, physicians and care providers from 60 countries – the largest group of international leaders in Alzheimer research and
care ever convened.

About Sanomune
Sanomune is a private biopharmaceutical start-up focused on neurological and autoimmune disorders. Sanomune’s lead product, SAN-61 is targeting the treatment of Alzheimer’s disease and other neurological conditions with a naturally-occurring, orally available protein.www.sanomune.com

About Cerebricon
Cerebricon Ltd. is a global collaborative and contract research organization, specializing in Preclinical models of CNS and PNS diseases for drug discovery and pharmacological research. Located in Kuopio, Finland with sales and marketing offices in London, UK and Los Angeles, USA. Cerebricon serves small, medium and large pharmaceutical companies as well as independent researchers and academic institutions around the globe. Cerebricon Ltd. is a completely privately owned company with fully proprietary staff and laboratories.www.cerebricon.com

For more information, please contact:

Rick Pauls
President
Sanomune Inc.
Phone: 204.477.7590
Fax: 204.453.1239